StemCells, Inc. (NASDAQ:STEM)

CAPS Rating: 2 out of 5

A biopharmaceutical company that operates in one segment, the development of novel cell-based therapeutics designed to treat human diseases and disorders.

Recs

0
Player Avatar Haugurafpeningum (85.94) Submitted: 11/8/2011 2:33:29 AM : Outperform Start Price: $1.97 STEM Score: -67.17

Technical Monthly

Featured Broker Partners


Advertisement